ITGA4 and relapsing-remitting multiple sclerosis: Blockade of CD49d with the humanized monoclonal antibody natalizumab suppresses trafficking of inflammatory leukocytes into the CNS [3] and leads to a significant decrease in the clinical relapse rate of the relapsing-remitting form of multiple sclerosis (RRMS) [6].